MOLECULAR THERAPEUTICS RESEARCH PROGRAM
MOLECULAR THERAPEUTICS RESEARCH PROGRAM
批准号:
7944597
负责人:
ALAN R EASTMAN
金额:
$5.43万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-21 至 2013-11-30
关键词:
ApoptosisApoptoticAreaBasic ScienceBiological MonitoringBiopsyCancer CenterCancer Center Support GrantCancer PatientCell Cycle RegulationCisplatinClinicalClinical TrialsCollaborationsDevelopmentDiagnosisDiseaseDisease OutcomeDrug effect disorderFacultyFatty-acid synthaseFosteringFundingGoalsGossypiumInvestigationMCL1 proteinMalignant neoplasm of pancreasMolecularMolecular TargetNeoadjuvant TherapyNew AgentsNon-Small-Cell Lung CarcinomaOutcomePaperPathway interactionsPharmaceutical PreparationsPhasePhase I Clinical TrialsProductivityProteasome InhibitorProteinsPublicationsResearchResearch PersonnelRoleSeriesSignal TransductionTestingTherapeuticTherapeutic Clinical TrialTherapeutic Human ExperimentationTranslatingTranslationsTumor Tissuecancer therapyclinical applicationdrug discoveryexpectationimprovedinhibitor/antagonistmalignant breast neoplasmmembernew technologynovelnovel strategiesnovel therapeuticsprogramssmoothened signaling pathwaytreatment strategytumortumor growthtumor progression
中文摘要
分子治疗学项目(MT)的目标是促进思想交流、合作和创新
英文摘要
The goal of the Molecular Therapeutics Program (MT) is to foster the exchange of ideas, cooperation, and
collaboration leading to translation of basic research focused on the identification and development of novel
therapeutics into clinical applications, and to use basic research to answer clinical questions related to
improving the treatment of cancer. The MT Program provides a forum for discussion and advancement of
new developments in target identification, drug discovery, and mechanisms of drug action, and for translating
these approaches into novel correlative and therapeutic clinical trials. The Program currently has 27
members from 7 departments and $8.2 millon in total funding, of which almost $4 million (61%) is from the
NCI. The productivity over the past 5 years exceeds 240 papers, including 16% intra-program and 26% interprogram
collaborative publications. Eighteen Program faculty participated in intra-program and 18 in interprogram
collaborations, providing strong evidence of a highly interactive research program. Recent
programmatic highlights include evidence for the role of the fatty acid synthase pathway as an independent
marker of breast cancer progression, and the recognition that it can be targeted to suppress tumor growth.
Other molecular targets under investigation include proteins in the Hedgehog signaling pathway, which is
frequently activated in non-small cell lung cancer. New agents such as novel proteasome inhibitors and
suppressors of the anti-apoptotic proteins Mcl-1 and Bcl-2 are under investigation, with the expectation of
bringing these drugs to clinical trial at Morris Cotton Cancer Center. Novel treatment strategies developed in
the MT Program that have been translated into Phase I clinical trials include the combination of cisplatin plus
the Chk1 inhibitor UCN-01. In is study serial tumor biopsies were used to monitor biological activity in tumor
tissue. Other investigators have developed novel technologies and complementary approaches to define
predictive markers and therapeutic strategies, and an important goal of the MT Program is to test these
ideas in correlative and therapeutic clinical trials at the NCCC. Also worthy of particular notice is a series of
Phase I and II clinical trials in pancreatic cancer using chemoradiation in the neoadjuvant setting that has
identified a promising treatment approach in this highly aggressive disease and demonstrates the Program's
impact on disease outcome in cancer patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cancer Biology and Molecular Therapeutics
-
批准号:7921845
-
项目类别:
-
资助金额:$10.2万
-
财政年份:2009
-
负责人:ALAN R EASTMAN
-
依托单位:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
-
批准号:7483072
-
项目类别:
-
资助金额:$30.38万
-
财政年份:2007
-
负责人:ALAN R EASTMAN
-
依托单位:
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
-
批准号:8633002
-
项目类别:
-
资助金额:$28.96万
-
财政年份:2007
-
负责人:ALAN R EASTMAN
-
依托单位:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
-
批准号:7629019
-
项目类别:
-
资助金额:$30.38万
-
财政年份:2007
-
负责人:ALAN R EASTMAN
-
依托单位:
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
-
批准号:9036264
-
项目类别:
-
资助金额:$29.86万
-
财政年份:2007
-
负责人:ALAN R EASTMAN
-
依托单位:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
-
批准号:7257577
-
项目类别:
-
资助金额:$30.38万
-
财政年份:2007
-
负责人:ALAN R EASTMAN
-
依托单位:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
-
批准号:7864084
-
项目类别:
-
资助金额:$30.38万
-
财政年份:2007
-
负责人:ALAN R EASTMAN
-
依托单位:
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
-
批准号:8499599
-
项目类别:
-
资助金额:$29.81万
-
财政年份:2007
-
负责人:ALAN R EASTMAN
-
依托单位:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
-
批准号:8074512
-
项目类别:
-
资助金额:$29.47万
-
财政年份:2007
-
负责人:ALAN R EASTMAN
-
依托单位:
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
-
批准号:9243917
-
项目类别:
-
资助金额:$29.86万
-
财政年份:2007
-
负责人:ALAN R EASTMAN
-
依托单位:
2006 Molecular Therapeutics of Cancer Gordon Research Conference
-
批准号:7269534
-
项目类别:
-
资助金额:$0.49万
-
财政年份:2006
-
负责人:ALAN R EASTMAN
-
依托单位:
2006 Molecular Therapeutics of Cancer Gordon Research Conference
-
批准号:7404425
-
项目类别:
-
资助金额:$0.49万
-
财政年份:2006
-
负责人:ALAN R EASTMAN
-
依托单位:
2006 Molecular Therapeutics of Cancer Gordon Research Conference
-
批准号:7161956
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2006
-
负责人:ALAN R EASTMAN
-
依托单位:
Cell Survival Pathways and Inhibitors in Leukemia
-
批准号:6620280
-
项目类别:
-
资助金额:$15.8万
-
财政年份:2002
-
负责人:ALAN R EASTMAN
-
依托单位:
Cell Survival Pathways and Inhibitors in Leukemia
-
批准号:6414417
-
项目类别:
-
资助金额:$15.83万
-
财政年份:2002
-
负责人:ALAN R EASTMAN
-
依托单位:
ABROGATION OF CELL CYCLE ARREST BY STAUROSPORINE ANALOGS
-
批准号:6173588
-
项目类别:
-
资助金额:$27.37万
-
财政年份:1999
-
负责人:ALAN R EASTMAN
-
依托单位:
ABROGATION OF CELL CYCLE ARREST BY STAUROSPORINE ANALOGS
-
批准号:2881971
-
项目类别:
-
资助金额:$27.39万
-
财政年份:1999
-
负责人:ALAN R EASTMAN
-
依托单位:
ABROGATION OF CELL CYCLE ARREST BY STAUROSPORINE ANALOGS
-
批准号:6377305
-
项目类别:
-
资助金额:$28.13万
-
财政年份:1999
-
负责人:ALAN R EASTMAN
-
依托单位:
Molecular Therapeutics (MT)
-
批准号:8804018
-
项目类别:
-
资助金额:$6.72万
-
财政年份:1997
-
负责人:ALAN R EASTMAN
-
依托单位:
MEETING ON CELL DEATH AND CANCER
-
批准号:3434321
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1993
-
负责人:ALAN R EASTMAN
-
依托单位:
海外基金